Nvidia Just Confirmed an Emerging AI Boom in Biotech

InvestorPlace2023-07-14

Trillion-dollar AI chipmaker Nvidia just announced a huge new partnership with biotech AI startup Recursion Pharmaceuticals.AI’s application in the field of biology holds the potential to unlock ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Jabba93
    2023-07-14
    Jabba93
    Thoughts?
  • Cedric77
    2023-07-14
    Cedric77
    Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses machine learning and artificial intelligence to discover and develop new medicines. The company's platform, called SHERLOCK, allows it to screen billions of data points to identify new drug targets and pathways. Recursion Pharmaceuticals' top 5 investors are: • Baillie Gifford & Co. (13.61%) • The Vanguard Group, Inc. (5.82%) • BlackRock Fund Advisors (4.94%) • MIC Capital Management UK LLP (4.58%) • Kinnevik AB (publ) (4.32%) The company's stock has been on a tear in recent months, rising over 600% since its IPO in February 2021. Some investors believe that the stock is overvalued, given that the company has yet to bring a drug to market. However, others believe that the company's platform has the potential
Leave a comment
2
1